Related Experiment Video
Updated: May 17, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens
Marie Lafitte1, Benoit Rousseau, Isabelle Moranvillier
1INSERM U1035, Bordeaux, France.
Background:
Pancreatic ductal adenocarcinoma is a deadly malignancy resistant to current therapies. It is critical to test new strategies, including tumor-targeted delivery of therapeutic agents. This study tested the possibility to target the transfer of a suicide gene in tumor cells using an oncotropic lentiviral vector.
Results:
Three cell surface markers were evaluated to target the transduction of cells by lentiviruses pseudotyped with a modified glycoprotein from Sindbis virus. Only Mucin-4 and the Claudin-18 proteins were found efficient for targeted lentivirus transductions in vitro. In subcutaneous xenografts of human pancreatic cancer cells models, Claudin-18 failed to achieve efficient gene transfer but Mucin-4 was found very potent. Human pancreatic tumor cells were modified to express a fluorescent protein detectable in live animals by bioimaging, to perform a direct non invasive and costless follow up of the tumor growth. Targeted gene transfer of a bicistronic transgene bearing a luciferase gene and the herpes simplex virus thymidine kinase gene into orthotopic grafts was carried out with Mucin-4 oncotropic lentiviruses. By contrast to the broad tropism VSV-G carrying lentivirus, this oncotropic lentivirus was found to transduce specifically tumor cells, sparing normal pancreatic cells in vivo. Transduced cells disappeared after ganciclovir treatment while the orthotopic tumor growth was slowed down.
Conclusion:
This work considered for the first time three aspect of pancreatic adenocarcinoma targeted therapy. First, lentiviral transduction of human pancreatic tumor cells was possible when cells were grafted orthotopically. Second, we used a system targeting the tumor cells with cell surface antigens and sparing the normal cells. Finally, the TK/GCV anticancer system showed promising results in vivo. Importantly, the approach presented here appeared to be a safer, much more specific and an as efficient way to perform gene delivery in pancreatic tumors, in comparison with a broad tropism lentivirus. This study will be useful in future designing of targeted therapies for pancreatic cancer.
Insights
Researchers developed a targeted gene therapy for pancreatic cancer using Mucin-4 oncotropic lentiviruses. This approach specifically targets tumor cells, sparing healthy ones, and shows promise in slowing tumor growth after ganciclovir treatment.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with limited treatment options.
- Targeted delivery of therapeutic agents is crucial for improving PDAC treatment efficacy.
- This study investigates oncotropic lentiviral vectors for targeted gene delivery in PDAC.
Purpose of the Study:
- To evaluate the potential of targeting pancreatic tumor cells using lentiviral vectors.
- To assess the specificity and efficiency of Mucin-4 as a tumor cell surface target.
- To demonstrate the in vivo efficacy of a suicide gene therapy system in pancreatic cancer models.
Main Methods:
- Lentiviruses were pseudotyped with modified Sindbis virus glycoproteins to target specific cell surface markers.
- Mucin-4 and Claudin-18 were evaluated for their ability to target lentiviral transduction in vitro and in vivo.
- Orthotopic pancreatic tumor xenografts were used to assess targeted gene transfer and therapeutic efficacy of the herpes simplex virus thymidine kinase/ganciclovir (TK/GCV) system.
Main Results:
- Mucin-4 demonstrated potent and specific targeting of human pancreatic tumor cells in vivo, unlike Claudin-18.
- Oncotropic lentiviruses specifically transduced tumor cells, sparing normal pancreatic cells.
- Ganciclovir treatment led to the disappearance of transduced cells and slowed tumor growth.
Conclusions:
- Targeted lentiviral gene delivery to orthotopically grafted human pancreatic tumor cells is feasible.
- The Mucin-4 targeting system offers a specific and safer alternative to broad-tropism lentiviruses for pancreatic cancer gene therapy.
- The TK/GCV suicide gene system combined with targeted lentiviral delivery shows promising therapeutic potential for pancreatic cancer.
